Gilead says it will charge governments $2,340 and private insurers $3,120 for a 5-day course of remdesivir, a treatment for Covid-19 patients.

This is an outrageous price for a drug that has demonstrated little to no ability to save lives or lower viral loads in patients. The few benefits it supposedly has are supported by trials that can only be described as flimsy. Remdesivir is not even approved by the U.S. Food and Drug Administration, having received only emergency use authorization.

As Peter Maybarduk, Public Citizen’s Access to Medicines Director, told the Financial Times, this is “a display of hubris and disregard for the public.”

Read full article on Forbes

Originally published on Forbes (June 29, 2020)